Table 4. Summary of activity according to arms of treatment.
| Outcome | GEM | PTX | GV | GT |
|---|---|---|---|---|
| Response rate | 18 | 13 | 23 | 32 |
| 95% CI | 9–30 | 6–24 | 13–35 | 20–45 |
| Disease control rate | 37 | 34 | 53 | 60 |
| 95% CI | 25–50 | 23–48 | 40–65 | 45–71 |
| Duration of responses | ||||
| Median (months) | 6.8 | 6.6 | 7.6 | 6.5 |
| Range | 4.6–15 | 4.2–9.0 | 5.0–10.2 | 5.8–8.2 |
| Survival | ||||
| Median (months) | 5.1 | 6.4 | 9.7 | 9.2 |
| 95% CI | 2.2–8.0 | 4.4–8.4 | 7.9–11.5 | 4.8–13.6 |
| 1-year survival probability | 29 | 25 | 32 | 44 |
| 95% CI | 17–41 | 13–37 | 20–44 | 32–56 |
| 2-year survival probability | 8 | 8 | 14 | 11 |
| 95% CI | 1–16 | 1–16 | 4–24 | 1–21 |
| Failure-free survival | ||||
| Median (months) | 3.3 | 3.7 | 4.1 | 4.5 |
| 95% CI | 2.6–4.0 | 2.9–4.5 | 2.9–5.3 | 2.8–5.6 |
| 6-month probability | 33 | 31 | 33 | 36 |
GEM=gemcitabine, PTX=paclitaxel, GV=gemcitabine plus vinorelbine, GT=gemcitabine plus paclitaxel.